Discover 138 paid clinical trials in South Bend, Indiana. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 138
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
for
Embryonal Rhabdomyosarcoma,
Location: Kalamazoo MI, Chicago IL, Oak Lawn IL, Maywood IL,
Sponsor: Children's Oncology Group
Sex: All
Age: 0 - 21
Code: NCT05304585
Phase3, Recruiting
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
Location: Kalamazoo MI, Chicago IL, Oak Lawn IL, Maywood IL,
Sponsor: Children's Oncology Group
Sex: All
Age: 0 - 30
Code: NCT04322318
Phase2, Recruiting
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Location: Kalamazoo MI, Chicago IL, Oak Lawn IL, Maywood IL,
Sponsor: PedAL BCU, LLC
Sex: All
Age: 0 - 22
Code: NCT04726241
Phase1, Phase2, Recruiting
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
for
Ganglioneuroblastoma, Nodular, Neuroblastoma
Location: Kalamazoo MI, Chicago IL, Oak Lawn IL, Park Ridge IL,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 0 - 30
Code: NCT06172296
Phase3, Recruiting
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
for
Acute Myeloid Leukemia
Location: Kalamazoo MI, Chicago IL, Oak Lawn IL, Maywood IL,
Sponsor: Children's Oncology Group
Sex: All
Age: 0 - 21
Code: NCT04293562
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
for
Acute Leukemia of Ambiguous Lineage,
Location: Kalamazoo MI, Chicago IL, Oak Lawn IL, Park Ridge IL,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 0 - 1
Code: NCT06317662
Phase2, Recruiting
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
for
Acute Coronary Syndrome
Location: Kalamazoo MI, Munster IN, Chicago IL, Glenview IL,
Sponsor: DalCor Pharmaceuticals
Sex: All
Age: 45+
Code: NCT05918861
Phase3, Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
for
Ovarian Neoplasms, Fallopian Tube Neoplasms,
Location: Kalamazoo MI, Chicago IL, Arlington Heights IL,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18+
Code: NCT07213804
Phase3, Recruiting
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
for
Cutaneous Melanoma, Stage II
Location: Kalamazoo MI, Chicago IL, Evanston IL, Park Ridge IL,
Sponsor: Melanoma and Skin Cancer Trials Limited
Sex: All
Age: 18+
Code: NCT03860883
Recruiting
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
for
Castration Levels of Testosterone,
Location: Kalamazoo MI, Chicago IL, Maywood IL, Grand Rapids MI,
Sponsor: SWOG Cancer Research Network
Sex: Male
Age: 18+
Code: NCT03678025
Phase3, Recruiting
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
for
Atrial Fibrillation (AF)
Location: Merrillville IN, Park Ridge IL, Winfield IL, Lansing MI,
Sponsor: Anthos Therapeutics, Inc.
Sex: All
Age: 65+
Code: NCT05712200
Phase3, Recruiting
Classroom Break, Cognition, and Fitness in Elementary School Children
for
Healthy Volunteers
Location: Royal Center IN
Sponsor: Purdue University
Sex: All
Age: 8 - 12
Code: NCT06258941
Phase1, Phase2, Recruiting
C-Brace Prospective Registry
for
Pareses, Lower Extremity
Location: Merrillville IN, Lansing MI, Livonia MI, Flint MI,
Sponsor: Otto Bock Healthcare Products GmbH
Sex: All
Age: 0+
Code: NCT04640584
Recruiting
A Study to Monitor Ambulatory Blood Pressure Monitoring in Hypogonadal Men Treated With Nasal Testosterone Gel
for
Hypogonadism
Location: Elwood IN, Indianapolis IN, Williamsville NY,
Sponsor: Acerus Pharmaceuticals Corporation
Sex: Male
Age: 18 - 70+
Code: NCT04976595
Recruiting
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
for
Atrial Fibrillation (AF)
Location: Merrillville IN, Indianapolis IN, Maumee OH,
Sponsor: Regeneron Pharmaceuticals
Sex: All
Age: 18+
Code: NCT07175428
Phase2, Recruiting
The RAPID - PE Study: RESCUE Advanced Protocol for the Treatment of Pulmonary Embolism
for
Pulmonary Embolism
Location: Hobart IN, Chicago IL, Indianapolis IN, Toledo OH,
Sponsor: Thrombolex, Inc.
Sex: All
Age: 0+
Code: NCT06433011
Recruiting
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
for
High-Risk Non-Muscle-Invasive Bladder Cancer
Location: Merrillville IN, Chicago Ridge IL, Glenview IL,
Sponsor: CG Oncology, Inc.
Sex: All
Age: 18+
Code: NCT06567743
Phase2, Recruiting
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
for
Hematuria - Cause Not Known
Location: Merrillville IN, Dayton OH, Madison WI, Nashville TN,
Sponsor: Pacific Edge Limited
Sex: All
Age: 18 - 70+
Code: NCT06394869
Recruiting
Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Location: Merrillville IN, Glenview IL, New Lenox IL, Carmel IN,
Sponsor: Dendreon
Sex: Male
Age: 18+
Code: NCT06134232
Phase2, Recruiting
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
for
Myelodysplastic Syndrome
Location: Crown Point IN, Chicago IL, Evanston IL, Maywood IL,